Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer.

about

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer.

Item

http://www.wikidata.org/entity/Q49178301

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer.

@en

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer.

@nl

type

Item

label

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer.

@en

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer.

@nl

prefLabel

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer.

@en

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer.

@nl

P1476

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer.

@en

P2093

A Cubillo

http://www.w3.org/2001/XMLSchema#string

B Belanger

http://www.w3.org/2001/XMLSchema#string

B Melichar

http://www.w3.org/2001/XMLSchema#string

B S Adiwijaya

http://www.w3.org/2001/XMLSchema#string

I Lang

http://www.w3.org/2001/XMLSchema#string

I Molnar

http://www.w3.org/2001/XMLSchema#string

J B Gallego

http://www.w3.org/2001/XMLSchema#string

J Fitzgerald

http://www.w3.org/2001/XMLSchema#string

J Kim

http://www.w3.org/2001/XMLSchema#string

J O Park

http://www.w3.org/2001/XMLSchema#string

P2860

Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme

Topoisomerase I inhibitors: camptothecins and beyond

Handling data below the limit of quantification in mixed effect models.

Missing data in model-based pharmacometric applications: points to consider.

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients

Nanovector-based therapies in advanced pancreatic cancer.

Pharmacogenetics of irinotecan disposition and toxicity: a review.

Clinical pharmacokinetics of irinotecan.

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.

Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.

P304

997-1005

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CPT.720

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28445610

http://www.w3.org/2001/XMLSchema#string

P932

5697569

http://www.w3.org/2001/XMLSchema#string